CSL's biosciences sales rise 19% in fiscal 1994
This article was originally published in Clinica
Executive Summary
The Biosciences division of CSL (Australia) saw its turnover rise 19% to Au$16.9 million ($13 million) in fiscal 1994 (ended June). CSL says it holds the major market share in Australian blood bank diagnostics and cell culture reagent businesses. The company has developed a diagnostic screening test for TB based on cell-mediated immunity (CMI) technology. "Interim results from clinical trials suggest this new test is superior to existing screening methods," CSL notes in its annual report.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.